Perspectiva general

Conference: February 24-25, 2025 | In-Person
This conference delves into the evolving regulatory landscape for advertising and promotion of biopharmaceuticals and medical devices, with a focus on innovation, compliance, and patient-centric communication. Attendees will explore cutting-edge topics such as the application of artificial intelligence in promotional review, the distinction between scientific communication and promotion, and strategies for engaging diverse patient populations.
Join thought leaders from industry, legal, public affairs, and government for interactive discussions that will shape policy, define strategic priorities, and provide actionable insights into regulatory expectations and best practices.
Designed for professionals at all career stages, this conference offers a comprehensive understanding of current FDA policies, emerging trends in digital marketing and disease awareness campaigns, and practical tools for optimizing promotional review processes. Network with experts from the FDA, industry, and regulatory agencies to tackle the challenges and opportunities in today's fast-evolving advertising and promotion space.
Agenda Update
We want to address the program adjustments necessitated by the recent HHS memorandum and the evolving nature of FDA participation in speaking events. We recognize the value of the insights provided by FDA regulators to our attendees. While the FDA cannot attend this meeting, we have been told that they may resume attending and speaking at events soon and we will continue to work with them to facilitate their immediate participation.
We work closely with FDA for our program content and strive to ensure the program agenda continues to be comprehensive to meet your professional needs and deliver the quality you have come to expect from DIA. We remain steadfast in our commitment to convening stakeholders from diverse sectors to drive medical product development and enhance patient outcomes through scientific collaboration and knowledge exchange. We look forward to your participation and contribution to our mission.
Need Approval in Order to Attend?
Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.
Participant Testimonials
It was a great event. The speakers and panels were very informative, relevant, and organizedwell. It was also a wonderful opportunity to network and meet new individuals who work in thesame/similar role at other companies. – James Chang, Associate Manager Regulatory Advertising and Promotion, Astellas
This conference is a great opportunity to learn recent trends in our industry, and hear about exciting issues hot topics. It was so great to see everyone in person again as well and network. – Kavita Vazirani, Principal Consultant, Opus Regulatory, Inc.
All levels of regulatory A&P expertise can benefit from it. Besides educational presentations, the face-to-face social networking aspect of this event was exceptionally good. Breaks after every session helped us refreshed and focused. – Iram Quraishi, Director Regulatory A&P, Takeda
Featured
Want to learn more about Advertising and Promotion Regulatory Affairs Conference? You've come to the right site!
Check out the great content lined up for the Advertising and Promotion Regulatory Affairs Conference
Welcome Video
Comité del programa
-
Nicol Lorraine George, PharmD, RPh Vice President, Promotional Review & Labeling Services
ProPharma Group, United States -
Georgina Lee, PharmD Executive Director, Regulatory Advertising and Promotion
Sage Therapeutics, United States -
Lynn Bowen, PhD Vice President, Regulatory Affairs Advertising Promotion & Labeling
Alkermes, Inc., United States -
Anthony Genovese, PharmD Group Leader, Regulatory Advertising and Promotion
Johnson and Johnson, United States -
Moulakshi Roychowdhury, JD, PharmD Global Head, Regulatory Affairs, Advertising & Promotion, Allergan Aesthetics
AbbVie, United States -
Virginia Foley VP Regulatory, Life Sciences & Healthcare
Constellation, Inc., United States -
Stephen Shinall, PhD Director of Regulatory Affairs
Biogen, United States -
Zoe Dunn President & CEO
Hale Advisors, Inc., United States
¿Tiene una cuenta?